Darmadi, Darmadi, et al. “An Efficacy and Safety Comparison of Regorafenib and Nivolumab in Unresectable Hepatocellular Cancer Patients: A Systematic Review”. Acta Medica Academica, vol. 53, no. 1, Apr. 2024, pp. 46-58, doi:10.5644/ama2006-124.443.